NASHVILLE - Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and Vanderbilt Health announced today results from a Phase 2a clinical trial evaluating ifetroban for preventing metastasis in patients with high-risk solid tumors.
The randomized, double-blind, placebo-controlled trial enrolled 29 participants with solid tumors including breast, lung, pancreatic, soft tissue, bladder, and renal cancers. The study met its primary endpoint, demonstrating that ifetroban was safe and well-tolerated. Adverse event rates related to treatment were similar between the placebo and ifetroban groups, with no serious adverse events in either group identified as treatment-related.
In a prespecified secondary endpoint, 17% of participants in the ifetroban arm experienced distant metastatic recurrence compared to 50% in the placebo arm (p=0.091). Three deaths due to distant metastatic disease occurred in the placebo arm, while none occurred in the ifetroban arm (p=0.037). The study involved 10 placebo-treated and 18 ifetroban-treated participants who were evaluated 12 months after completion of therapy.The positive trial news contributed to Cumberland’s strong stock performance, with shares delivering a 164% return over the past six months. The company currently holds a market capitalization of $85.4 million and generated $41.94 million in revenue over the last twelve months, though it remains unprofitable with an EPS of -$0.5. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value.
The trial was not powered for efficacy as it was primarily designed to assess safety. Participants received treatment for 12 months after completing all cancer-related therapies and surgical procedures, then were followed for an additional 12 months.
Ifetroban is a thromboxane A2 receptor antagonist designed to block platelet activation and aggregation. Cumberland is also evaluating the drug in Phase 2 trials for Duchenne Muscular Dystrophy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis. The drug has been tested in clinical trials enrolling over 1,400 people.
The information is based on a press release statement from Cumberland Pharmaceuticals.
In other recent news, Cumberland Pharmaceuticals reported mixed financial results for the first quarter of 2026. The company experienced a 5% increase in adjusted revenue, reaching $9.1 million. However, despite the revenue growth, Cumberland Pharmaceuticals faced a net loss of $3.3 million. These developments reflect ongoing challenges and strategic adjustments within the company. Investors have shown caution in response to the reported loss, indicating a focus on the company’s future financial health. The earnings results underscore the importance of monitoring Cumberland Pharmaceuticals’ future performance and strategic initiatives. These recent developments highlight the need for investors to stay informed about the company’s financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for CPIX plus thousands of other stocks and find your next hidden gem with massive upside.